Pharmacoeconomics
Conditions
Interventions
experience group:bicyclol group
control group:Licorice and glycyrrhizinic acid group
Sponsors
The First Affiliated Hospital of Zhengzhou University
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: Retrospective cohort formation method: the cases of patients with cervical cancer / ovarian malignancy / endometrial cancer admitted to the hospital from January 1, 2019 to December 31, 2021 were retrospectively collected. They were divided into two groups according to the oral liver protection drugs actually treated by the patients: the clinical data of gynecological malignant tumor patients who only used bicyclol tablets and glycyrrhizic acid oral preparations for liver protection treatment were basically collected at the ratio of 1:1. I patients meet the formation criteria of the queue II age = 18 years old III total bilirubin (TBIL), alkaline phosphatase (ALP), aspartate aminotransferase (AST) and alanine aminotransferase (ALT) in patients before chemotherapy = 1.5 × Upper normal value (ULN)
Exclusion criteria
Exclusion criteria: I patients with dicyclohol tablets combined with glycyrrhizic acid oral preparation II patients with hepatitis virus infection and receiving antiviral treatment III patients with serious heart disease, kidney disease and other serious organic diseases IV patients undergoing cellular immunotherapy V patients with other malignant tumors
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Liver biochemistry;cost;rate of adverse reaction; | — |
Countries
China
Contacts
Public ContactShuzhang Du
The First Affiliated Hospital of Zhengzhou University
Outcome results
None listed